Government Shutdown: What Patients with Brain Tumors & Care Partners Need to Know The potential for a government shutdown is currently leading national news. If Congress can’t agree on a new budget to fund all of the federal government’s departments, agencies, and programs for Fiscal Year 2024 by Friday, September 29 (or pass what’s known as a “Continuing Resolution” or “CR” to give themselves more time), many of […] September 26, 2023
Guest Blog: A Patient and Philosopher Goes to the Biggest Brain Tumor Research Conference of the Year Glioblastoma patient and NBTS Board member, Adam Hayden, reflects on attending the 2022 Society for Neuro-Oncology Annual Meeting The Philosopher-Patient I was diagnosed with glioblastoma in the final year of my graduate studies, ironically specializing in the Philosophy of Science. Ironic because what could be more absurd than a philosopher with brain cancer?! The brain […] December 16, 2022
Q&A: A New Treatment Approved for Certain Brain Tumors In late June 2022, the U.S. Food and Drug Administration (FDA) granted accelerated approval to a new treatment combination that will now be available as an option for certain brain tumor patients. The approved combination of two oral drugs, called dabrafenib (brand name: Tafinlar) and trametinib (brand name: Mekinist), is for the treatment of advanced tumors […] August 9, 2022
New Treatment Approved for Certain Glioma Patients On June 22, 2022, the U.S. Food and Drug Administration (FDA) granted accelerated approval to a new treatment combination that will now be available as an option for certain brain tumor patients. The FDA approved the combination of two oral drugs called dabrafenib (brand name: Tafinlar) and trametinib (brand name: Mekinist) for the treatment of advanced tumors […] June 28, 2022
NBTS Brain Tumor Clinical Trials Report: Q4 2021 It can be hard to keep track of new clinical trial opportunities opening across the United States, especially as we continue to navigate the public health crisis created by the coronavirus (COVID-19). There are many clinical trials actively enrolling patients, and this report provides a summary of the studies that have recently opened or started […] January 13, 2022